Medication info
Xpujeong 20 mg (Esomeprazole Magnesium Trihydrate)

Xpujeong 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
KS Pharmaceutical Co., Ltd.
Appearance
Pink, round, film-coated tablet
Packaging
28 tablets/box [(7 tablets/Alu-Alu*4)]
Approval status
Active

MFDS item code 201906448 · Approved 2019.09.16 · Insurance code 059000380

Summary

Main use
Treatment of acid-related disorders (e.g., reflux, ulcers, and Zollinger-Ellison syndrome); eradication therapy; treatment of gastrointestinal disorders caused by NSAIDs
Who uses it
Adults · Children
Adult dosage
This medication should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Antibiotic combination therapy for Helicobacter pylori eradication Administer this medication 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. No clinical trials lasting more than 4 weeks have been conducted. 4) Patients requiring continuous treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment No dose adjustment is necessary. Use caution because there is limited experience administering this medication to patients with severe renal failure. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. The dose of this medication should not exceed 20 mg in patients with severe hepatic impairment. 6. Older adults No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years or older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age There is no experience with administering this medication to children under 12 years of age.

Ingredients

Manufacturer
KS Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (e.g., reflux, ulcers, and Zollinger-Ellison syndrome); eradication therapy; treatment of gastrointestinal disorders caused by NSAIDs

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • Helicobacter pylori-associated duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • NSAID-related gastric ulcers
  • NSAID-related duodenal ulcers
  • Zollinger-Ellison syndrome
  • rebleeding due to gastric ulcers
View approved original text

This medication is used for the long-term maintenance therapy of erosive esophagitis due to gastroesophageal reflux disease and to prevent the recurrence of esophagitis. It is also effective in relieving gastroesophageal reflux disease symptoms without esophagitis. It is included in combination antibiotic therapy for the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection. It aids in the short-term treatment of upper gastrointestinal symptoms that occur with nonsteroidal anti-inflammatory drug use and is also beneficial for the treatment and prevention of gastric and duodenal ulcers in patients requiring ongoing NSAID therapy. This is a very useful drug for the treatment and prevention of various gastrointestinal disorders.

Dosage and Administration

Adult dosage

This medication should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Antibiotic combination therapy for Helicobacter pylori eradication Administer this medication 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. No clinical trials lasting more than 4 weeks have been conducted. 4) Patients requiring continuous treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment No dose adjustment is necessary. Use caution because there is limited experience administering this medication to patients with severe renal failure. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. The dose of this medication should not exceed 20 mg in patients with severe hepatic impairment. 6. Older adults No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years or older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age There is no experience with administering this medication to children under 12 years of age.

Precautions

This drug should not be used by patients who are allergic to certain ingredients or to this drug itself. Caution is advised for patients allergic to penicillin or macrolide antibiotics, especially when used in combination for the eradication of Helicobacter pylori. Patients taking certain heart-related medications or with a history of myocardial infarction, as well as breastfeeding women, are also advised against using this drug. This drug contains a dye called Yellow No. 5, and patients with an allergy to this component should use it carefully. Rarely, various side effects such as blood-related diseases, allergic reactions, electrolyte imbalances, neurological symptoms, gastrointestinal problems, liver function abnormalities, skin reactions, etc. may occur. Regular monitoring is necessary during prolonged use, and if symptoms change during medication, the physician should be consulted immediately. This drug lowers stomach acidity and may increase the risk of certain bacterial infections; therefore, if diarrhea persists, healthcare professionals should be notified. Long-term or high-dose use may increase the risk of fractures, so caution is needed in patients at risk for osteoporosis. This drug has numerous drug interactions, particularly with antibiotics, antiviral agents, anticoagulants, and anticonvulsants, and should be taken according to the doctor's instructions. Safety data on use during pregnancy is limited, so pregnant women should consult healthcare providers before use. It is recommended that breastfeeding women do not take this drug. There are no specific antidotes for overdose, so supportive treatment according to symptoms is required, and it should be kept out of the reach of children. Moreover, transferring the drug to other containers poses risks of accidents and affects quality; thus, caution should be exercised.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorders, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, mucocutaneous syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, Lhermitte's syndrome, acute generalized exanthematous pustulosis, eosinophilia with systemic symptoms associated drug reaction, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, substernal chest pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid enlargement, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue swelling, ulcerative stomatitis, earache, tinnitus, anemia, hypopigmented anemia, cervix lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, dry mouth, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, cramps, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, anorexia, apathy, increased appetite, confusion, exacerbation of depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disturbances, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal pruritus, erythematous rash, papular rash, otitis media, olfactory dysfunction, taste loss, parageusia, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal strictures, esophageal ulcers, esophageal varices, gastric ulcers, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, discoid lupus erythematosus, gastric fundus polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to prevent air or moisture from entering. Additionally, it is best to keep the drug at room temperature, between 1 degree and 30 degrees, avoiding extremes of temperature.

Appearance and packaging

Appearance

Pink, round, film-coated tablet

Package unit

28 tablets/box [(7 tablets/Alu-Alu*4)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.